Almirall completes deal with AstraZeneca in respiratory disease
04-Nov-2014
- Spain
Almirall announced this strategic transaction on July 30th, which includes an upfront cash consideration upon completion of $875 million and, additionally, up to $1.22 billion related to development, launch, and sales-related milestones. AstraZeneca has also agreed to make various sales-related payments.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.